Bigfinite's BigEngine is a SaaS platform for acquiring, visualizing and recording regulated data from manufacturing sites, analyzing it in real time and detecting inefficiencies and discovering its causes.
Pep is an IT entrepreneur and has been working in IT for the last 25 years. He pioneered Linux adoption in the 90s, cloud in the 2000s and big data in recent years. While he has a theoretical economics and maths profile, his early career was as a software developer for the chemical industry at m2r. Later, he served as CTO & COO of an IT consulting firm, leading a team of 200+ engineers. In 2003, Pep created his first IT company with a clear customer centric focus. Two more followed. In 2013, Pep's next venture took shape: BigFinite is the result of this initial spark that immediately caught the imagination of his long-time professional collaborators, Pere and Toni. Pep is an Economist (University of Barcelona) with background in Engineering.
Pere is a visionary entrepreneur and investor. With more than 30 years in the biotech & pharma software industry, Pere first created M2R SA in the mid '80s pioneering this industry. M2R was acquired by Aspen Technology Inc. in 2000. His second company, SVS, founded in the late '90s, became the global reference for GMP compliance knowledge for pharma and biotech processes. SVS was bought by Azbil Corporation (Japan) in 2013. Pere was currently investing in diverse ventures, but bigfinite caught his attention from the beginning and he is now actively working in the company as Chairman. Pere is Chemical Engineer by the IQS.
Toni previously was head of R+D+i at Telstar. He was also quality Manager in Labware, Group Telstar. Since 1996 Toni has managed software projects for international pharma industries through the process supply chain (R+D, clinical phase, manufacturing, quality, equipments, warehousing and logistics), as well as projects to implement the 3 ICH (Q8, Q9 and Q10) and was also involved in audits and validation tasks (he's an ISO 9001 auditor). Toni pioneered the introduction of applications to manage the electronic quality of the manufacturing processes in the pharma and biotech market. He is also a postgraduate in Quality Systems in Industry and Pharmaceutical Research. Toni doctorate in Astrophysics at Barcelona University.
Llorenç is doctor in chemical engineering by the IQS. He started his professional career already linked to the science applied IT working at IBM on Research on Quantum Chemistry and Parallel Computation. He later was technical manager and owner at M2R until it was acquired by Aspen Technologies, where he became Senior Principal Engineer. He has an extremely extensive activity in publications and an intensive activity in regulatory organizations (ISA, ISPE).
Mark is Technology Director at Genentech. Previously he was general manager of the Life Sciences and Specialty Chemicals division at Aspen Technology and before at Sequencia as vice president of sales and marketing. Previously he had more than 15 years of experience in control and automation of batch processes, first as a process control engineer at GE Plastics and Hoechst-Celanese and later as director of project engineering for PID. Mark holds a B.S. in chemical engineering from the University of California at Santa Barbara.
Thomas has held a number of positions at Pfizer Inc., most recently within the Development Operations and Worldwide Regulatory Strategy organization. Prior to these roles, he was the Head of Strategy for Pfizer’s Biotherapeutics and Bioinnovation Center (BBC). He joined Pfizer as Development Strategy Lead, Strategic Management Group (SMG) within Pfizer Global Research and Development (PGRD). While at Pfizer, Thomas was responsible for initiating a number collaborative innovation initiatives, including that as a co-founding member of MIT/NEWDIGS. He currently serves on the Advisory Boards of a number of emerging biotech companies and foundations. Thomas obtained his Ph.D. in Biological Chemistry from the California College of Medicine, University of California, Irvine.and his M.B.A. from the Marshall School of Business, University of Southern California. He currently serves on the Advisory Boards of a number of emerging biotech companies, foundations and the Center for Biomedical Innovation at MIT.
Stephan is Chief Financial Officer at Takeda Pharmaceuticals, and previously Chief Financial Officer at Novartis Vaccines in China & Tianyuan Bio-Pharma. With more than 17 years of experience in the Pharmaceutical industry Stephan gained deep international experience spanning Middle East, China, Africa, and Europe/US, covering all financial aspects of a Pharma company – from R&D, to Production to Sales in corporate, regional and local roles. Stephan is a trained MBA/Chemical Engineer (Wirtschaftingenieur) and received further education in Finance and Legal at MIT, UIUC and the University of Liverpool.
Wim was one of the founders of COMPEX and was in charge to develop the international business in LIMS, PLM and MES and setting up the international offices. Because of Compex high tech and organization capabilities the group was acquired by Siemens headquarter in 2001, to include COMPEX MES, LIMS, PLM and Research Suite solutions in the SIEMENS portfolio. He has a large experience in the software industry for pharma and biotech and several publication and European and international projects in this sector. He also advises several tech companies in the area of software solutions for the regulated industry. Wim is engineer, Master in applied sciences, Physics, Electronics, Information & Communication Technology by the University of Gent, where he is also professor of ICT management.